<DOC>
	<DOCNO>NCT02099071</DOCNO>
	<brief_summary>This prospective , single-center , double-blind , randomize , placebo-controlled , ascend single oral dose food interaction Phase 1 study . It evaluate safety , tolerability , pharmacokinetics pharmacodynamics ascend single oral dos ACT-389949 healthy male subject . It also investigate effect food pharmacokinetics , safety , tolerability single dose ACT-389949 .</brief_summary>
	<brief_title>Study Investigate Tolerability , Safety , Pharmacokinetics , Pharmacodynamics ACT-389949</brief_title>
	<detailed_description />
	<criteria>Signed informed consent prior studymandated procedure . Healthy Caucasian male subject age 18 45 year ( inclusive ) screening . Subjects must agree use reliable method contraception . No clinically significant finding physical examination screening . Body mass index ( BMI ) 18.0 30.0 kg/m^2 ( inclusive ) screening . Systolic blood pressure ( SBP ) 100145 mmHg , diastolic blood pressure ( DBP ) 5090 mmHg , pulse rate ( PR ) 4590 bpm ( inclusive ) measure screen . 12lead ECG without clinically relevant abnormality , measure screening . Body temperature ( T° ) 35.537.5°C screen prior ( first ) dosing . Total differential white blood cell ( WBC ) count strictly within normal range screen Day −1 . Creactive protein ( CRP ) level 5 mg/L . Hematology clinical chemistry result ( total differential WBC count CRP ) deviate normal range clinically relevant extent screening . Coagulation urinalysis test result deviate normal range clinically relevant extent screening . Non smoker , define never smoke achieve cessation ≥ 6 month screen . Negative result urine drug screen screen . Subjects allow conduct genetic analysis whole blood consist measuring level messenger ribonucleic acid ( mRNA ) expression mechanistic biomarkers Nformylpeptide receptor 2 ( FPR2 ) proteins involve inflammation . Ability communicate well investigator local language , understand comply requirement study . Known allergic reaction hypersensitivity excipient drug formulation . History clinical evidence disease , and/or existence surgical medical condition , might interfere absorption , distribution , metabolism excretion study drug . Previous history recurrent fainting , collapse , syncope , orthostatic hypotension , vasovagal reaction . Veins unsuitable intravenous ( i.v . ) puncture either arm . Treatment another investigational drug within 3 month prior screen participate four investigational drug study within 1 year prior screen . History clinical evidence alcoholism drug abuse within 3year period prior screen . Excessive caffeine consumption . Treatment prescribed overthecounter ( OTC ) medication within 2 week prior ( first ) study drug administration five halflives medication , whichever longer . Any history immunosuppressive treatment . Chronic disease include recur period flareups remission . History atopic allergy ( include asthma , urticaria , eczematous dermatitis ) . Signs infection ( viral , systemic fungal , bacterial protozoal ) within 4 week prior ( first ) study drug administration . History acute chronic obstructive lung disease ( treat treat ) . History subarachnoid hemorrhage hemolytic uremic syndrome . Interval begin P wave begin QRS complex ( PQ/PR interval ) &lt; 120 m screening . Loss 250 mL blood , equivalent amount plasma , within 3 month prior screen . Positive result hepatitis serology , except vaccinated subject subject past resolve hepatitis , screen . Positive result human immunodeficiency virus serology screen . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol . Legal incapacity limit legal capacity screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>ACT-389949</keyword>
</DOC>